Clinical trial · Interventional
C752 for Refractory/Relapsed B Cell Non-Hodgkin Lymphoma
A Single-arm, Open-label Clinical Study to Assess the Safety and Efficacy of the C752 CAR-T Cells for Patients With CD19+ Refractory/Relapsed B Cell Non-Hodgkin Lymphoma
NCT06210243CI-TRIAL-00086122terminatedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Due to the PI's determination
Summary
Brief summary (as posted)
It is a single-arm, open-label clinical study to assess the safety and efficacy of the C752 CAR-T Cells for patients with CD19+ refractory/relapsed B cell non-Hodgkin lymphoma.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| CAR-T | — | UNRESOLVED | — |
| Lymphoma, B-Cell | B-Cell Malignant Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| C752 | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- C752
- interventionNames
- Biological: C752
Primary outcomes (2)
- measure
- The incidence and severity of adverse events (AEs)
- timeFrame
- 1 year
- measure
- Dose Limiting Toxicities
- timeFrame
- First 28 days s after C752 injection
Secondary outcomes (3)
- measure
- Objective response rate (ORR)
- timeFrame
- 1 year
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Written informed consent in accordance with federal, local, and institutional guidelines, Males and females ≥18 years of age at the time of consent * Documented diagnosis of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma * Have progression by least one systemic treatment and no available standard of care treatment. * At least one measurable lesion by Lugano 2014 * Expected survival ≥ 12 weeks * Have an ECOG performance status of 0 or 1 * Adequate organ function * Screening test indicates histopathological CD19 + if the subject received CD19-targeted therapy * Women of childbearing age must have a negative pregnancy test, and agree to take effective contraception during the trial Exclusion Criteria: * Treatment with any prior HSCT, gene therapy product, cell therapy product ect. * Central nervous system involvement * HBV/HCV * HIV infection * Concurrent use of systemic steroids or immunosuppression * Uncontrolled active infection * Wash-out period of from the last anti-cancer treatment * Active second malignancy * Have not recovered from the effects of previous therapy * Have psychological or physical conditions that do not permit compliance with the protocol * Pregnant or nursing (lactating) women
References
Publications (0)
Data not yet available
No reference posted for this study.